Institutional investors back a $300 million flotation for inhaled pulmonary fibrosis therapies, signalling stronger risk appetite for clinical-stage biotech listings and sharpening focus on tolerability, delivery technology and trial milestones.
Thursday’s Nasdaq debut for Avalyn Pharma is a test of whether specialist institutions still fund clinical-stage biotech in size, with Burghley Capital tracking the signal from an upsized $300 million offering priced at $18 a share. The Boston-based company puts 16.7 million shares into the market, lifting what begins as roughly $200 million in early marketing into a materially larger raise at pricing.
The final structure reflects a late-stage expansion from 11.8 million to 16.7 million shares, a 41.5% increase in base deal terms immediately before pricing. In the initial filing estimates, net proceeds are flagged near $234.2 million, whilst the gross figure at pricing stands near $386.5 million before underwriting discounts and commissions.
Avalyn enters the float with around $178.4 million of cash at the start of its latest reporting year, and the added capital is positioned to fund the next sequence of clinical milestones without near-term refinancing. Underwriters hold a 30‑day option for 2.5 million additional shares which, if exercised in full over that option window, adds roughly $58 million to gross proceeds. Trading is set for the Nasdaq Global Select Market under AVLN, with settlement expected on Friday, subject to customary closing conditions.
Avalyn’s implied post-pricing, fully diluted valuation sits near $1 billion — a level that sets a clear bar for patience in a sector where outcomes can be binary. James Barker, Burghley Capital Pte. Ltd.’s private equity director, distilled the logic as “specialist capital is paying for a sequenced plan and a credible runway, not for a near-term earnings story”, but warned that “pricing discipline only holds if milestones arrive on time and in order”.
The investable thesis centres on tolerability and delivery. Pulmonary fibrosis is estimated to affect about 300,000 people in the United States at present, with median survival typically three to five years after diagnosis. Routine practice shows only about 30% of idiopathic pulmonary fibrosis patients receive antifibrotic therapy, whilst around 50% discontinue within the first year because adverse effects make persistence difficult.
Avalyn’s platform uses nebulised delivery to target diseased lung tissue directly, aiming for high local concentrations with lower systemic exposure. In comparative pharmacokinetic work, AP01 reaches 35‑fold higher peak epithelial lining fluid concentrations than oral pirfenidone with around one‑fifteenth the systemic exposure, a profile designed to reduce blood-level exposure linked to gastrointestinal side effects. Barker’s view is that “delivery is not a detail, it is the product, because adherence is where efficacy assumptions break down in the real world”.
The disclosed clinical experience spans more than 150 participants and exceeds 3,000 cumulative months of exposure across trials completed so far. The Phase IIb MIST study in progressive pulmonary fibrosis targets enrolment completion around mid-year, with topline data anticipated in the second half of the following year, whilst the Phase II AURA study in idiopathic pulmonary fibrosis aims for enrolment completion in the second half of the following year before subsequent read-outs. Ahead of the offering, Novo Holdings holds a 13% stake.
The market backdrop shows why delivery innovation attracts capital. The global idiopathic pulmonary fibrosis treatment market is valued at about $4,362.3 million in the latest full-year estimate and is forecast to reach about $7,521.6 million over the coming decade, implying a 6.1% compound annual growth rate across that horizon.
For investors weighing the risk, the central discipline is time. Across a full drug development cycle, the probability of a phase I asset reaching approval is often cited near 20%. Avalyn’s net loss in its most recent full financial year widens to about $95.1 million from about $55.5 million in the prior year, whilst industry benchmarks place average outlay per asset near $2.5 billion and investment required to reach approval near $893.1 million over the journey to market; the last private financing round before listing raises about $111.6 million. Barker sets out the trade-off, “public investors are underwriting the timetable to data, so the valuation only works if the next gates arrive with clinical clarity”.
The market’s reaction over the first weeks of trading will determine whether demand persists once deal mechanics fade and clinical execution takes centre stage, and Burghley Capital’s focus is likely to remain on the same question institutions ask after every successful bookbuild: does the science deliver on schedule?
About Burghley Capital
Founded in 2017, Burghley Capital Pte. Ltd. (UEN: 201731389D) is a global investment management firm headquartered in Singapore, known for long-only asset management expertise. It combines disciplined research with tailored investment approaches and dedicated financial advisory support for institutional investors and private clients worldwide. Further information is available at https://burghleycapital.com/resources. Media enquiries: Martin Wei, m.wei@burghleycapital.com, https://burghleycapital.com.
